Table of Contents
Asthma Drug Market Overview
Asthma Drug companies provide asthma management relies on two primary medication types: quick-relief (rescue) and long-term control (maintenance) medications.
Quick-relief medications, such as short-acting beta-agonists like albuterol, offer immediate relief by relaxing airway muscles during attacks.
Long-term control medications, including inhaled corticosteroids like budesonide and long-acting beta-agonists like salmeterol, are taken daily to reduce inflammation and prevent symptoms.
Additional treatments, such as leukotriene modifiers and monoclonal antibodies, provide targeted options for severe cases.
Further, utilizing a combination of these therapies is crucial for effective asthma management and enhancing patients’ quality of life.
Market Drivers
The global asthma drug companies/market is influenced by several key factors. Including the increasing prevalence of asthma linked to urbanization and pollution and advancements in pharmaceutical research that yield innovative therapies and personalized treatments.
Improved diagnostic tools enable early detection, while heightened awareness and education empower patients to pursue treatment.
Additionally, better healthcare infrastructure enhances access to therapies and regulatory support, and the rise of biologic treatments and substantial investments in research and development further drive market growth. Collectively, these factors enhance asthma management and promote effective treatment options.
Market Size
The Global Asthma and COPD Drugs Market is projected to reach approximately USD 64.6 billion by 2033, up from USD 38.2 billion in 2023. This represents a compound annual growth rate (CAGR) of 5.6% from 2024 to 2033.
List of Major Companies
These are the top ten companies operating in the Asthma Drug Market:
- Abbott
- Merck
- GSK
- Novartis
- Johnson-n-Johnson
- Bristol-Myers-Squibb
- Sanofi
- Pfizer
- Teva-Pharmaceutical
- AbbVie
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott
Abbott Laboratories plays a crucial role in the asthma drug companies/market by developing and marketing treatments that enhance respiratory health.
The growing prevalence of asthma drives the global market for asthma treatments, and Abbott has contributed by offering inhaled corticosteroids and combination inhalers.
Further, Abbott’s 2023 acquisition of Bigfoot Biomedical is a notable development. Which enhances its portfolio in digital health and chronic disease management.
Complementing its respiratory health initiatives with advanced monitoring and drug delivery systems. Furthermore, Abbott’s consistent investment in product innovation supports growth across its medical devices and pharmaceuticals segments.
Geographical Presence
Abbott Laboratories operates globally across multiple regions, including North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa.
Its largest market is the United States, where it leads in medical devices, diagnostics, and nutrition. Key growth markets include Brazil and Mexico in Latin America and China and India in Asia-Pacific, driven by rising healthcare demands. In Europe, significant operations are established in the UK, Germany, France, and Italy.
The company employs local partnerships, research and development investments, and regulatory adaptations to enhance its market presence and innovation. It positions itself favorably for sustained growth in the global healthcare landscape.
Recent Developments
- In October 2024, Abbott Laboratories obtained a contract from the Defense Logistics Agency Troop Support in Philadelphia to supply medical equipment and accessories.
- In September 2023, Abbott acquired Bigfoot Biomedical, enhancing its position in the diabetes market and complementing its FreeStyle Libre® continuous glucose monitoring technology for personalized diabetes management.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck has a notable presence in the asthma drug companies/sector, primarily through its product DULERA®, a combination of mometasone furoate and formoterol fumarate.
Which is used to manage asthma in patients aged 12 and older. This drug, while effective in controlling symptoms, carries warnings related to long-acting beta-agonists due to the risk of asthma-related death in certain populations.
Further, in terms of recent developments, Merck has been expanding its portfolio with strategic acquisitions, including the 2023 purchase of Prometheus Biosciences for $10.8 billion.
This acquisition strengthens Merck’s immunology pipeline and has the potential to impact treatments for immune-mediated diseases, further diversifying its therapeutic offerings.
Geographical Presence
Merck & Co., Inc., also known as MSD outside the U.S. and Canada, is a leading global healthcare company with a significant presence in over 140 countries.
Headquartered in Kenilworth, New Jersey, the company operates primarily in North America, with the U.S. as its largest market, while also maintaining substantial operations in Europe, Asia-Pacific, Latin America, and the Middle East.
Merck’s strategy includes localized operations, collaborative partnerships with governments and healthcare organizations, and targeted research and development to address regional health challenges.
This multifaceted approach enables Merck to leverage diverse market opportunities and enhance health outcomes worldwide.
Recent Developments
- In October 2024, Merck signed a licensing and collaboration agreement with Mestag Therapeutics to develop novel fibroblast therapies for inflammatory diseases.
- In October 2024, Merck acquired CN201, an innovative bispecific antibody in clinical trials for B-cell-related diseases.
GSK
Company Overview
| Establishment Year | 2000 |
| Headquarter | London, England, UK |
| Key Management | Emma Walmsley (CEO) |
| Revenue (US$ Bn) | $ 37.7 Billion (2022) |
| Headcount | ~ 70,000 (2024) |
| Website | https://www.gsk.com/ |
About GlaxoSmithKline
GSK continues to be a key player in the asthma drug companies/sector, particularly through its advancements in biological treatments for severe asthma.
The company recently made significant progress with its drug depemokimab, a long-acting anti-IL-5 monoclonal antibody, which has shown promising results in phase III trials.
Depemokimab could revolutionize asthma treatment by offering a six-month dosing schedule, making it more convenient for patients managing severe asthma.
Additionally, GSK is expanding its respiratory pipeline with acquisitions, such as the $1.4 billion purchase of Aiolos Bio, giving it access to AIO-001, a potential treatment targeting the TSLP pathway for asthma and other respiratory conditions. These efforts highlight GSK’s ongoing commitment to advancing asthma care with innovative therapies.
Geographical Presence
GlaxoSmithKline plc (GSK) is a global healthcare company headquartered in Brentford, England, with a significant geographical presence that spans North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
The United States and Canada represent key markets, while the UK serves as the hub for its operations. In the Asia-Pacific region, China and India are pivotal in expanding access to medicines and vaccines.
GSK is also active in Brazil and Mexico, focusing on public health initiatives in Latin America, and has a strong operational base in South Africa, serving as a hub for African operations.
This diversified presence allows GSK to mitigate market risks and tailor healthcare solutions to meet regional needs, reinforcing its commitment to improving global health.
Recent Development
- In May 2024, GSK announced that phase III trials SWIFT-1 and SWIFT-2 demonstrated depemokimab’s efficacy and safety over placebo in adults and adolescents with severe asthma linked to type 2 inflammation and elevated eosinophil counts.
- In January 2024, GSK acquired Aiolos, gaining access to AIO-001, a long-acting TSLP monoclonal antibody in phase II development for adult asthma and potentially chronic rhinosinusitis with nasal polyps.
Novartis
Company Overview
| Establishment Year | 1996 |
| Headquarter | Basel, Switzerland |
| Key Management | Vasant Narasimhan (CEO) |
| Revenue (US$ Bn) | $ 45.4 Billion (2023) |
| Headcount | ~ 76,057 (2023) |
| Website | https://novartis.com/ |
About Novartis
Novartis remains a prominent player in the asthma drug companies/sector, continually advancing its respiratory treatments.
One of its notable developments is the investigational three-drug combination therapy, Enerzair Breezhaler, which was shown to be as effective as existing treatments for improving the quality of life of patients with uncontrolled asthma in phase 3 trials.
In terms of strategic moves, Novartis recently completed its $3.5 billion acquisition of Chinook Therapeutics, expanding its precision medicine portfolio.
Though primarily focused on kidney diseases, it demonstrates Novartis’ broader commitment to innovative therapies.
Furthermore, Novartis’ generics division, Sandoz, has been expanding its portfolio of respiratory treatments, including key acquisitions such as Oriel Therapeutics, which adds new inhalable drugs targeting asthma and COPD.
Geographical Presence
Novartis AG, a leading global healthcare company headquartered in Switzerland, operates in over 140 countries, with a strong presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
The United States represents the largest market, while significant operations in Germany, France, and China drive innovation in pharmaceuticals, particularly in oncology and cardiology.
Novartis emphasizes local partnerships to enhance market access and tailors its research and development initiatives to meet regional healthcare challenges.
Through investments in sustainability and a commitment to improving healthcare access, Novartis continues to adapt its offerings to diverse populations worldwide.
Recent Development
- In September 2024, Novartis partnered with Generate: Biomedicines to create protein therapeutics across multiple disease areas.
- In September 2024, Novartis sold Worldwide Rights to DESFERAL (deferoxamine) to MITEM Pharma.
Johnson-n-Johnson
Company Overview
| Establishment Year | 1886 |
| Headquarter | New Brunswick, New Jersey, U.S. |
| Key Management | Joaquin Duato (CEO) |
| Revenue (US$ Bn) | $ 85.1 B (2023) |
| Headcount | ~ 134,400 (2023) |
| Website | https://www.jnj.com/ |
About Johnson & Johnson
Johnson & Johnson has made strides in the asthma drug companies/sector, with a strong focus on expanding its immunology and respiratory portfolio.
In 2024, the company completed its acquisition of Proteologix, a biotechnology company developing bispecific antibodies, including those targeting pathways involved in asthma.
These antibodies, like PX-128 and PX-130, have the potential to transform treatment for patients with moderate to severe asthma by addressing multiple disease-driving mechanisms.
This acquisition underscores J&J’s strategy to strengthen its presence in immunology and respiratory diseases.
Additionally, the company continues to grow its innovative medicine portfolio through other acquisitions, such as the $2 billion purchase of Ambrx Biopharma, which further enhances its capabilities in developing targeted therapies.
Geographical Presence
Johnson & Johnson (J&J) has a strong global presence, enabling it to address varied healthcare needs. The U.S. is the headquarters and largest market, with Canada and Mexico also significant.
In Europe, J&J operates in key countries like the UK, Germany, and France, with Belgium as its regional hub.
The Asia-Pacific, particularly China and India, is vital for growth, while Latin America, especially Brazil and Argentina, is focused on expanding consumer health products.
Furthermore, J&J is enhancing its presence in the Middle East and Africa to leverage emerging market potential.
This geographical diversity allows J&J to adapt to local regulations and market demands, supporting its ongoing growth and stability.
Recent Developments
- In June 2024, J&J acquired Proteologix, Inc., a private biotechnology firm specializing in bispecific antibodies for immune-mediated diseases.
- In June 2024, J&J acquired Ambrx Biopharma, a clinical-stage company specializing in synthetic biology for next-generation antibody-drug conjugates (ADCs).
Bristol-Myers-Squibb
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $ 45.01 Billion (2023) |
| Headcount | ~ 34,000 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) is expanding its presence in the asthma and respiratory drugs sector through innovative therapies and strategic acquisitions.
Historically focused on oncology and immunology, BMS is developing a strong pipeline of respiratory treatments.
It is bolstered by its acquisition of Proteologix, which enhances its immunology portfolio with bispecific antibody treatments for immune-mediated diseases.
In 2023, BMS further diversified its therapeutic capabilities by acquiring RayzeBio for $4.1 billion, marking a significant entry into radiopharmaceuticals.
These initiatives underscore BMS’s commitment to advancing innovative treatments across various therapeutic areas, including asthma and respiratory conditions.
Geographical Presence
Bristol Myers Squibb (BMS) is a global biopharmaceutical company with a robust geographical presence that bolsters its research, development, and distribution capabilities.
The company generates significant revenue primarily in the United States and has a strong presence in key European markets, including the UK, Germany, France, and Italy.
In the Asia-Pacific region, BMS operates notably in Japan, China, and India while also expanding in Latin America, especially Brazil and Mexico.
By navigating diverse regulatory environments and forming partnerships with local firms, BMS enhances market access and conducts representative clinical trials, positioning itself for continued growth in the sector.
Recent Developments
- In October 2024, BMS received US FDA approval for Opdivo to treat adults with resectable non-small cell lung cancer.
- In September 2024, BMS secured approval from the US FDA for its first-in-class schizophrenia drug, Cobenfy (xanomeline-trospium).
Sanofi
Company Overview
| Establishment Year | 1973 |
| Headquarter | Paris, France |
| Key Management | Paul Hudson (CEO) |
| Revenue (US$ Bn) | $ 50.2 Billion (2022) |
| Headcount | ~ 86,088 (2023) |
| Website | http://www.sanofi.com/ |
About Sanofi
Sanofi S.A. is a prominent player in the asthma treatment market, particularly recognized for Dupixent (dupilumab), a biologic aimed at type 2 inflammation in moderate-to-severe asthma patients.
In 2024, the company reported positive phase 2 study results for rilzabrutinib, an innovative oral therapy for moderate-to-severe asthma, showing significant reductions in asthma control loss events and symptom improvements.
This development enhances Sanofi’s respiratory and immunology pipeline, which continues to expand with Dupixent’s growing indications and global regulatory approvals.
Furthermore, Sanofi is advancing additional respiratory treatments, reinforcing its leadership through ongoing research and strategic acquisitions.
Geographical Presence
Sanofi S.A., headquartered in Paris, operates in over 100 countries and specializes in diabetes, cardiovascular diseases, oncology, immunology, and rare diseases.
Its notable presence spans North America (U.S. and Canada), Europe (Germany and the UK), Asia-Pacific (China and Japan), and Latin America (Brazil and Mexico), where it emphasizes vaccines and diabetes care.
In the Middle East and Africa, the company focuses on essential medications and public health. Sanofi adapts its operations to local healthcare needs, invests in regional R&D, and forms strategic partnerships to improve market access and foster innovation.
Recent Developments
- In October 2024, Sanofi sold a 50% stake in its consumer health business, Opella, to Clayton Dubilier Rice.
- In September 2024, Sanofi invested US$27 million in a clinical-stage biopharmaceutical company, Ventyx Biosciences.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer Inc. is actively expanding its focus on respiratory diseases through strategic acquisitions and developments.
A notable move is the $6.7 billion acquisition of Arena Pharmaceuticals, which includes etrasimod, currently in phase 3 trials for immuno-inflammatory conditions, with potential applications in asthma treatment. This acquisition aligns with Pfizer’s strategy to enhance its inflammation and immunology portfolio.
Additionally, Pfizer is advancing its respiratory treatment initiatives through its acquisition of ReViral, a company specializing in therapies for respiratory syncytial virus (RSV), further strengthening its respiratory drug development efforts.
Geographical Presence
Pfizer Inc., based in New York City, is a prominent global pharmaceutical firm with a broad geographical footprint.
The United States is its largest market in North America, generating significant revenue through robust R&D and manufacturing efforts.
In Europe, Pfizer operates primarily in the UK, Germany, France, and Italy, emphasizing innovative drug development and partnerships.
The Asia-Pacific region, especially China and Japan, is crucial for growth and is supported by local collaborations. In Latin America, Brazil and Mexico play key roles in increasing medication access.
At the same time, South Africa and the UAE are vital markets in the Middle East and Africa, focusing on public health initiatives. Pfizer’s global presence facilitates the accessibility of its innovative therapies and vaccines to diverse populations.
Recent Development
- In June 2022, Pfizer acquired ReViral, a biopharmaceutical company targeting antiviral treatments for respiratory syncytial virus (RSV), including sisunatovir, an oral inhibitor that prevents RSV from fusing with host cells.
- In December 2021, Pfizer acquired Arena, a clinical-stage company developing innovative therapies for various immuno-inflammatory diseases.
Teva-Pharmaceutical
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 37,851 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals is making notable strides in the asthma drug companies/sector, particularly with its innovative ProAir Digihaler.
Later, this digital rescue inhaler features sensors that connect to a mobile app, enabling patients and healthcare providers to monitor inhaler usage and manage asthma symptoms effectively.
Offering real-time data on inhalation patterns enhances personalized asthma care. Teva is also advancing therapies like reslizumab, a monoclonal antibody that effectively reduces asthma exacerbations in severe cases.
Additionally, the company is exploring collaborations, including a partnership with Biolojic Design to develop antibody-based treatments for asthma and atopic dermatitis, further expanding its respiratory offerings.
Geographical Presence
Teva Pharmaceuticals, based in Petah Tikva, Israel, is a leading global company in the pharmaceutical sector, focusing on generic and specialty medicines.
It operates extensively across North America, Europe, Latin America, the Middle East, Africa, and Asia. In the U.S., Teva is a key player in the generic market, while in Canada, it provides a broad range of therapeutic products.
The company is expanding in Latin America, especially in Brazil and Mexico, and addressing local healthcare needs in the Middle East and Africa through strategic partnerships.
Additionally, Teva is increasing its presence in Asia, notably in India and Japan. At last, its growth strategy emphasizes substantial investments in research and development, adaptation to local markets, and strategic collaborations.
Recent Developments
- In October 2024, Teva Pharmaceuticals introduced a generic version of Sandostatin LAR Depot in the US.
- In June 2020, Teva launched a digital inhaler and drug combination in the U.S. with built-in sensors that connect to a phone to manage asthma and COPD symptoms.
AbbVie
Company Overview
| Establishment Year | 2012 |
| Headquarter | North Chicago, Illinois, United States |
| Key Management | Richard A. Gonzalez (CEO) |
| Revenue (US$ Bn) | $ 50.3 Billion (2023) |
| Headcount | ~ 50,000 (2023) |
| Website | http://abbvie.com/ |
About AbbVie
AbbVie Inc. has made strategic advancements in the asthma drug companies/sector through its immunology portfolio.
Although not a primary focus, the company is expanding its presence in respiratory care through partnerships and acquisitions.
Moreover, a notable development is AbbVie’s acquisition of DJS Antibodies, which could enhance their antibody therapies targeting inflammation and is relevant for respiratory diseases like asthma.
Additionally, AbbVie’s acquisition of Allergan in 2020 expanded its reach into biologics, which may further contribute to its asthma-related treatment pipeline in the future.
Geographical Presence
AbbVie Inc., based in North Chicago, Illinois, is a prominent global biopharmaceutical company with a strong presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
In the U.S., its main market, AbbVie, emphasizes R&D and manufacturing, featuring key products such as Humira and Imbruvica.
Further, the company is active in several European nations, including the UK, Germany, France, and Italy, focusing on drug development and market access.
In the Asia-Pacific region, Japan and China represent significant markets, while Brazil and Mexico are key areas for growth in Latin America.
AbbVie’s strategy emphasizes localized innovation and partnerships to strengthen its global healthcare footprint.
Recent Developments
- In October 2024, AbbVie announced the FDA approval of VYALEV™ (foscarbidopa and foslevodopa) as the first subcutaneous 24-hour infusion levodopa therapy for motor fluctuations in advanced Parkinson’s disease.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
